HR Execs on the Move

Natrol subsidiary of Plethico Pharmaceuticals Li

www.natrol.com

 
Natrol, Inc. subsidiary of Plethico Pharmaceuticals Limited is a Chatsworth, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.natrol.com
  • 21411 Prairie St
    Chatsworth, CA USA 91311
  • Phone: 818.739.6000

Executives

Name Title Contact Details

Similar Companies

Clover Biopharmaceuticals

Founded in 2007, we are a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases. Our vision is to empower humanity with a healthier future through transformative science. Our mission is to leverage the Trimer-Tag™ technology platform and manufacturing capabilities for the discovery, development and commercialization of novel vaccines and biologic therapies.

CardioRisk

CardioRisk is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette`s Disorder.

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.

Nutravail Technologies

Nutravail Technologies is a Chantilly, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.